Debt-to-equity of NRX Pharmaceuticals, Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: NRX Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
NRX Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -128%, a 3.2% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

NRX Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-128%	+4%	+3.2%	30 Sep 2025
Q2 2025	-120%	+37%	+24%	30 Jun 2025
Q1 2025	-125%	+98%	+44%	31 Mar 2025
Q4 2024	-123%	+272%	+69%	31 Dec 2024
Q3 2024	-133%	+4205%	+97%	30 Sep 2024
Q2 2024	-157%	-494%	-147%	30 Jun 2024
Q1 2024	-223%	-336%	-297%	31 Mar 2024
Q4 2023	-395%	-451%	-806%	31 Dec 2023
Q3 2023	-4338%	-4379%	-10636%	30 Sep 2023
Q2 2023	337%	+259%	+330%	30 Jun 2023
Q1 2023	113%	-448%	-80%	31 Mar 2023
Q4 2022	56%	+2791%		31 Dec 2022
Q3 2022	41%	+255%		30 Sep 2022
Q2 2022	78%	+219%		30 Jun 2022
Q1 2022	561%	+684%		31 Mar 2022
Q4 2021	-2735%	-2642%	-2833%	31 Dec 2021
Q3 2021	-214%	-160%	-299%	30 Sep 2021
Q2 2021	-141%	-55%	-65%	30 Jun 2021
Q1 2021	-124%	+877%	+88%	31 Mar 2021
Q4 2020	-93%	-183%	-204%	31 Dec 2020
Q3 2020	-54%	-92%	-238%	30 Sep 2020
Q2 2020	-85%			30 Jun 2020
Q1 2020	-1000%			31 Mar 2020
Q4 2019	90%			31 Dec 2019
Q3 2019	39%			30 Sep 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.